The contradictory results by Ellidag et al. (33) and Stein et al. (38) might be caused by the effects of treatments in RRMS patients since previous studies have indicated that the expression of FGF23 might be influenced by medication (40). This evidence concerns the gene FGF23 and relapsing-remitting multiple sclerosis.